Pediatric pulmonology sits at the center of some of the most prevalent and complex respiratory conditions affecting children. Asthma, cystic fibrosis, bronchopulmonary dysplasia, obstructive sleep apnea, and interstitial lung disease each carry distinct care protocols, monitoring requirements, and administrative demands. As childhood respiratory conditions have grown in prevalence—driven in part by air quality, environmental factors, and improved survival of preterm infants who go on to develop chronic lung conditions—pediatric pulmonology practices have seen sustained growth in patient volumes without equivalent growth in the specialist workforce.
The Prevalence Burden in Pediatric Respiratory Medicine
The Centers for Disease Control and Prevention (CDC) reports that asthma affects approximately 4.5 million children under the age of 18 in the United States, making it the most common chronic disease of childhood. Asthma remains a leading cause of emergency department visits, hospitalizations, and missed school days among children—a burden that could be reduced with more consistent outpatient management and follow-up. The Cystic Fibrosis Foundation reports that more than 40,000 people in the United States live with cystic fibrosis, with most diagnosed in childhood. CF care has been transformed by CFTR modulators—highly effective but extremely expensive drugs that require ongoing prior authorization, monitoring, and patient education.
These are conditions that require long-term engagement from the care team, not episodic intervention. That makes the administrative infrastructure of a pediatric pulmonology practice—the systems that ensure patients get their appointments, their medications, and their monitoring—critically important to clinical outcomes.
Scheduling Complexity in Pulmonology Practice
Pediatric pulmonology appointments often involve multiple components: a clinical visit with the physician or nurse practitioner, a pulmonary function test (PFT) conducted by a respiratory therapist, and in some cases a 6-minute walk test or bronchoprovocation challenge. Scheduling these multi-component visits requires coordination across provider calendars and equipment availability—a process that is time-consuming when managed manually and prone to scheduling errors that send families to appointments where a required test room or therapist is unavailable.
VAs trained in pulmonology scheduling workflows manage this coordination systematically. They ensure that PFT slots are booked in conjunction with clinical visits, confirm equipment availability for specialized tests, and send families preparation instructions in advance. For cystic fibrosis patients who attend a formal CF Care Center, VAs coordinate the multi-disciplinary clinic visits that include the pulmonologist, a CF nurse educator, a dietitian, a social worker, and a physical therapist—ensuring that all team members are scheduled and that families receive coordinated appointment confirmations rather than a cascade of separate scheduling calls.
Medication Authorization for Expensive Respiratory Therapies
CFTR modulator therapy—drugs like ivacaftor, lumacaftor/ivacaftor, and elexacaftor/tezacaftor/ivacaftor—has revolutionized cystic fibrosis treatment but carries annual costs that can exceed $300,000 per patient. These drugs require prior authorization from commercial and government payers, and authorizations typically require documentation of CFTR mutation testing results, baseline lung function, and clinical justification. VAs managing the authorization lifecycle for these medications—submission, follow-up, appeals when denied, and tracking of renewal timelines—protect patients from gaps in therapy that can result in lung function decline.
Biologic agents used in severe pediatric asthma, including dupilumab and mepolizumab approved for pediatric populations, carry similar authorization requirements. A VA systematically tracking the authorization calendar across a practice's biologic-treated patients ensures that no patient misses a dose due to an administrative oversight.
Family Education and Follow-Up Between Visits
Outcomes in pediatric asthma and CF depend heavily on what happens between clinic visits—whether families are following home therapy protocols, whether inhaler technique is correct, and whether early signs of exacerbation are recognized and acted on. VAs support this between-visit management by conducting structured follow-up calls, collecting patient-reported outcomes, and delivering education reminders in accordance with care plan goals established by the clinical team.
Practices looking to build stronger administrative infrastructure for their pediatric pulmonology programs can review VA solutions at Stealth Agents, which provides trained healthcare VAs for specialty pediatric clinic workflows.
With respiratory conditions among the leading causes of childhood morbidity, the administrative systems that support consistent care deserve the same attention as the clinical protocols themselves.
Sources
- Centers for Disease Control and Prevention — Childhood Asthma Data and Surveillance, 2023
- Cystic Fibrosis Foundation — Patient Registry Annual Data Report, 2022
- Cystic Fibrosis Foundation — CFTR Modulator Therapy Overview